Aardvark Therapeutics, Inc. (AARD)
About Aardvark Therapeutics, Inc.
Aardvark Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing novel, small-molecule therapeutics to activate innate homeostatic pathways for the treatment of metabolic diseases. It is focused on on developing selective compounds, targeting Bitter Taste Receptors (TAS2Rs) for hunger-associated conditions. Its product candidate, ARD-101, is an oral gut-restricted small-molecule agonist of certain TAS2Rs expressed in the gut lumen for which have initiated a Phase 3 clinical trial for hyperphagia associated with PWS.
This profile is unclaimed. An authorized representative can claim it to add details and earn the Verified badge.
Financial summary
- Net income
- -$57.6M
- Total assets
- $117.2M
- Market cap
- $80.3M
Source: SEC EDGAR · updated Jun 7, 2026
Financial statements
Income statement
- Revenue
- $0
- Operating expenses
- $62.7M
- Operating income
- -$62.7M
- Income tax
- $0
- Net income
- -$57.6M
- EPS (basic)
- $-2.93
- EPS (diluted)
- $-2.93
Balance sheet
- Total assets
- $117.2M
- Current assets
- $111.9M
- Total liabilities
- $10.5M
- Current liabilities
- $10.5M
- Shareholders’ equity
- $106.6M
Cash flow
- Operating cash flow
- -$54.2M
- Investing cash flow
- -$49.7M
- Financing cash flow
- $89.2M
- Net cash flow
- -$14.6M
Statements via Polygon.io (SEC filings)
15-minute delayed · data by Polygon.io
Past year · hover for prices
52-week range
- Market cap
- $80.3M
- EPS (diluted)
- $-2.93
- Shares outstanding
- 12.7M
- Open
- —
- Day range
- –
- Prev close
- —
- Volume
- —
- IPO date
- Feb 13, 2025
Aardvark Therapeutics, Inc. (AARD) Stock Price
- Reported a net loss of $57.6M.
- Trading 64% below its 52-week high.
Automatically generated from public filings and market data. Informational only — not investment advice or a recommendation to buy or sell any security.
No reviews yet. Be the first to review Aardvark Therapeutics, Inc..
Write a review
News about Aardvark Therapeutics, Inc.
News & sentiment via Polygon.io
Aardvark Therapeutics, Inc.: frequently asked questions
Is Aardvark Therapeutics, Inc. an American company?
Aardvark Therapeutics, Inc. is a US-based company headquartered in San Diego, California, listed in the americancompanies.com directory of American companies. Its American-origin credentials have not yet been independently verified.
Where is Aardvark Therapeutics, Inc. headquartered?
Aardvark Therapeutics, Inc. is headquartered in San Diego, California, United States.
Is Aardvark Therapeutics, Inc. publicly traded?
Yes — Aardvark Therapeutics, Inc. is a publicly traded company. Its stock trades under the ticker symbol AARD on the NASDAQ.
What does Aardvark Therapeutics, Inc. do?
Aardvark Therapeutics, Inc. is an American Pharmaceuticals company in the Health & Beauty sector.
